ROLE OF BIOCHEMICAL MARKERS AMONG COVID-19 PATIENTS AND THEIR ASSOCIATION WITH SEVERITY OF DISEASE
DOI:
https://doi.org/10.22159/ajpcr.2024v17i10.52183Keywords:
COVID-19, biochemical markers, pandemic, severityAbstract
Objectives: The present study was aimed to evaluate the levels of biomarkers (D-dimer, Procalcitonin [PCT], lactate dehydrogenase [LDH], interleukin [IL]-6, and C-reactive protein [CRP]) among coronavirus disease 2019 (COVID-19) patients visiting/admitted in Government Medical College Jammu and analyze their association with the severity of disease.
Methods: The study was conducted on 100 COVID-19-positive patients 18–75 years of age of either sex, visiting/admitted in Government Medical College Jammu, for a period of 6 months. The serum glucose levels, creatine phosphokinase, LDH, liver function tests, renal function tests, and various biochemical COVID-19 markers such as CRP, serum ferritin, IL-6, D-dimer, and PCT were analyzed.
Results: In the present study, it was observed that when patients were divided according to the severity of disease, there was a significant difference in the mean levels of total bilirubin, serum sodium, serum potassium, D-dimer, SpO2, and duration of symptoms in a mild and severe group of patients, while there was no significant difference in the parameters such as IL-6, ferritin, CRP, PCT, LDH, and other routine biochemistry parameters. When a comparison was done between both the groups according to SpO2, only the mean levels of serum total bilirubin were significant.
Conclusion: Thus, it is concluded that serum bilirubin was significantly elevated in mild, moderate, and severe groups of patients. Further research should be conducted to find some biomarkers which are specific to COVID-19 only.
Downloads
References
Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The pathogenesis of coronavirus disease 2019 (COVID-19): Evaluation and prevention. J Immunol Res. 2020 Jul 10;2020:1357983.
Mritunjaya M, Pavithra V, Neelam R, Jhanvi P, Halami PM, Ravindra PV. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol. 2020 Oct 7;11:570122.
WHO Director-General’s Opening Remarks at the Media Briefing on COVID19-22 December 2021. Available from: https://www.who. int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---22-december-2021
Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564-7.
WHO. Coronavirus Disease 2019 (COVID-19) Situation Report-114; 2020. Available from: https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/situation-reports [Last accessed on 2020 May 13].
Kadhim AS, Abdullah YJ. Serum levels of interleukin6, ferritin, Creactive protein, lactate dehydrogenase, Ddimer, and count of lymphocytes and neutrophils in COVID19 patients: Its correlation to the disease severity. Biomed Biotechnol Res J. 2021;5:69-73.
Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020 Nov;195:219-25.
Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020 Aug;56(2):106051.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
Prasad S, Patel S, Behera AK, Gitismita N, Shah S, Nanda R, et al. Early biochemical markers in predicting the clinical outcome of Covid-19 patients admitted in tertiary care hospital in Chhattisgarh, India. J Lab Physicians. 2022;14:295-305. doi: 10.1055/s-0042-1742631
Giemza-Stokłosa J, Islam MA, Kotyla PJ. Hyperferritinaemia: An iron sword of autoimmunity. Curr Pharm Des. 2019;25(27):2909-18.
Asghar MS, Haider Kazmi SJ, Khan NA, Akram M, Hassan M, Rasheed U, et al. Poor prognostic biochemical markers predicting fatalities caused by COVID-19: A retrospective observational study from a developing country. Cureus. 2020 5;12(8):e9575.
Falcão Gonçalves P, Menezes Falcão L, Duque Pinheiro I. Procalcitonin as biomarker of infection: Implications for evaluation and treatment. Am J Ther. 2017 May;24(3):e243-9.
Grondman I, Pirvu A, Riza A, Ioana M, Netea MG. Biomarkers of inflammation and the etiology of sepsis. Biochem Soc Trans. 2020 Feb 28;48(1):1-14.
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020 Jun;215:108427.
Burtis CA, Ashwood ER, Bruns DE, editors. Teitz Textbook of Clinical Biochemistry and Molecular Diagnostics. 4th ed. St Louis, MO: Elsevier Saunders; 2006. p. 2263.
Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561-6.
Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599-606.
Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304-7.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566-74.
Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine. 2020 3;23:100375.
Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856-62.
Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al. COVID-19 mortality risk assessment: An international multi-center study. PLoS One. 2020 Dec 9;15(12):e0243262.
Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020;24(1):525.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-99.
Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791-6.
Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of coronavirus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24:3404-10.
Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
Gemcioglu E, Davutoglu M, Catalbas R, Karabuga B, Kaptan E, Aypak A, et al. Predictive values of biochemical markers as early indicators for severe COVID-19 cases in admission. Future Virol. 2021;16:353-67.
Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: A systematic review and meta-analysis. Crit Care. 2020;24(1):255.
Published
How to Cite
Issue
Section
Copyright (c) 2024 RACHNA SABHARWAL1, RAJESH MAHAJAN2, PALLAVI MAHAJAN3*, FAYAZ AHMAD WANI4, ANIMESH MAHAJAN5
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
